CONMED Statistics
Total Valuation
CONMED has a market cap or net worth of $1.34 billion. The enterprise value is $2.15 billion.
| Market Cap | 1.34B |
| Enterprise Value | 2.15B |
Important Dates
The last earnings date was Wednesday, November 5, 2025, after market close.
| Earnings Date | Nov 5, 2025 |
| Ex-Dividend Date | Sep 15, 2025 |
Share Statistics
CONMED has 30.97 million shares outstanding. The number of shares has decreased by -0.29% in one year.
| Current Share Class | 30.97M |
| Shares Outstanding | 30.97M |
| Shares Change (YoY) | -0.29% |
| Shares Change (QoQ) | -0.01% |
| Owned by Insiders (%) | 0.86% |
| Owned by Institutions (%) | 117.01% |
| Float | 30.69M |
Valuation Ratios
The trailing PE ratio is 21.11 and the forward PE ratio is 9.29. CONMED's PEG ratio is 1.38.
| PE Ratio | 21.11 |
| Forward PE | 9.29 |
| PS Ratio | 1.00 |
| Forward PS | 0.92 |
| PB Ratio | 1.33 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 9.00 |
| P/OCF Ratio | 7.99 |
| PEG Ratio | 1.38 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.54, with an EV/FCF ratio of 14.47.
| EV / Earnings | 33.63 |
| EV / Sales | 1.60 |
| EV / EBITDA | 9.54 |
| EV / EBIT | 14.01 |
| EV / FCF | 14.47 |
Financial Position
The company has a current ratio of 2.10, with a Debt / Equity ratio of 0.85.
| Current Ratio | 2.10 |
| Quick Ratio | 0.84 |
| Debt / Equity | 0.85 |
| Debt / EBITDA | 3.64 |
| Debt / FCF | 5.73 |
| Interest Coverage | 4.72 |
Financial Efficiency
Return on equity (ROE) is 6.60% and return on invested capital (ROIC) is 5.15%.
| Return on Equity (ROE) | 6.60% |
| Return on Assets (ROA) | 4.15% |
| Return on Invested Capital (ROIC) | 5.15% |
| Return on Capital Employed (ROCE) | 7.66% |
| Revenue Per Employee | $345,505 |
| Profits Per Employee | $16,428 |
| Employee Count | 3,900 |
| Asset Turnover | 0.58 |
| Inventory Turnover | 1.66 |
Taxes
In the past 12 months, CONMED has paid $21.44 million in taxes.
| Income Tax | 21.44M |
| Effective Tax Rate | 25.07% |
Stock Price Statistics
The stock price has decreased by -42.13% in the last 52 weeks. The beta is 0.98, so CONMED's price volatility has been similar to the market average.
| Beta (5Y) | 0.98 |
| 52-Week Price Change | -42.13% |
| 50-Day Moving Average | 47.43 |
| 200-Day Moving Average | 54.04 |
| Relative Strength Index (RSI) | 37.62 |
| Average Volume (20 Days) | 463,309 |
Short Selling Information
The latest short interest is 846,967, so 2.73% of the outstanding shares have been sold short.
| Short Interest | 846,967 |
| Short Previous Month | 1.02M |
| Short % of Shares Out | 2.73% |
| Short % of Float | 2.76% |
| Short Ratio (days to cover) | 5.46 |
Income Statement
In the last 12 months, CONMED had revenue of $1.35 billion and earned $64.07 million in profits. Earnings per share was $2.05.
| Revenue | 1.35B |
| Gross Profit | 761.13M |
| Operating Income | 153.82M |
| Pretax Income | 85.51M |
| Net Income | 64.07M |
| EBITDA | 225.86M |
| EBIT | 153.82M |
| Earnings Per Share (EPS) | $2.05 |
Balance Sheet
The company has $38.93 million in cash and $853.75 million in debt, giving a net cash position of -$814.82 million or -$26.31 per share.
| Cash & Cash Equivalents | 38.93M |
| Total Debt | 853.75M |
| Net Cash | -814.82M |
| Net Cash Per Share | -$26.31 |
| Equity (Book Value) | 1.01B |
| Book Value Per Share | 32.57 |
| Working Capital | 347.46M |
Cash Flow
In the last 12 months, operating cash flow was $167.69 million and capital expenditures -$18.74 million, giving a free cash flow of $148.96 million.
| Operating Cash Flow | 167.69M |
| Capital Expenditures | -18.74M |
| Free Cash Flow | 148.96M |
| FCF Per Share | $4.81 |
Margins
Gross margin is 56.49%, with operating and profit margins of 11.42% and 4.75%.
| Gross Margin | 56.49% |
| Operating Margin | 11.42% |
| Pretax Margin | 6.35% |
| Profit Margin | 4.75% |
| EBITDA Margin | 16.76% |
| EBIT Margin | 11.42% |
| FCF Margin | 11.05% |
Dividends & Yields
This stock pays an annual dividend of $0.80, which amounts to a dividend yield of 1.85%.
| Dividend Per Share | $0.80 |
| Dividend Yield | 1.85% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 39.02% |
| Buyback Yield | 0.29% |
| Shareholder Yield | 2.13% |
| Earnings Yield | 4.78% |
| FCF Yield | 11.12% |
Analyst Forecast
The average price target for CONMED is $54.00, which is 24.80% higher than the current price. The consensus rating is "Hold".
| Price Target | $54.00 |
| Price Target Difference | 24.80% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on September 10, 2001. It was a forward split with a ratio of 1.5:1.
| Last Split Date | Sep 10, 2001 |
| Split Type | Forward |
| Split Ratio | 1.5:1 |
Scores
CONMED has an Altman Z-Score of 2.17 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.17 |
| Piotroski F-Score | 7 |